SCHEMBL5706337

SCHEMBL5706337

C[SiH](C)CCOC(=O)Cc1ccc(I)cc1F

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
AKR1B1 P15121 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
MAP2K1 Q02750 4/20 0.32
HPGD P15428 2/20 0.32
MAP2K2 P36507 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HTT P42858 1/20 0.32
KDM1A O60341 1/20 0.32
MEN1 O00255 2/20 0.31
MAPT P10636 2/20 0.31
KMT2A Q03164 2/20 0.31
PIM1 P11309 1/20 0.31
CAMK2B Q13554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4518509 0.81 L3MBTL1 (0.43) ALDH1A1SMN1; SMN2L3MBTL1TDP1MAP2K1
SCHEMBL4504422 0.81 TAAR1 (0.36) ALDH1A1SMN1; SMN2AKR1B1TAAR1L3MBTL1
SCHEMBL4513880 0.79 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2AKR1B1TAAR1L3MBTL1
SCHEMBL4517422 0.78 AKR1B1 (0.40) ALDH1A1SMN1; SMN2AKR1B1MAP2K1HPGD
SCHEMBL2006540 0.71 AKR1B1 (0.43) AKR1B1MAP2K1MAP2K2
SCHEMBL257063 0.70 AKR1B1 (0.35) AKR1B1MAP2K1MAP2K2
SCHEMBL27855541 0.69 AKR1B1 (0.36) AKR1B1MAP2K1MAP2K2PIM1CAMK2B
SCHEMBL2403273 0.69 L3MBTL1 (0.40) ALDH1A1SMN1; SMN2L3MBTL1LMNAHPGD
SCHEMBL14223949 0.68 MCL1 (0.44) ALDH1A1SMN1; SMN2L3MBTL1TDP1KDM4E
SCHEMBL2129344 0.67 ALDH1A1 (0.42) ALDH1A1AKR1B1LMNAMAP2K1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1696899-A1 METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B ALLERGAN, INC. (US) 2006-09-06 EP disclosed
WO-2005058301-A1 METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B ALLERGAN, INC. (US) 2005-06-30 WO disclosed